Loading...

NFL Biosciences SA

ALNFL.PA•EURONEXT
Healthcare
Biotechnology
€1.13
€-0.05(-4.24%)

NFL Biosciences SA (ALNFL.PA) Stock Overview

Explore NFL Biosciences SA’s financial performance, market position, analyst ratings, and future outlook.

Meyka AI Score

B

Score: 61.8/100

Key Financials

Market Cap14.2M
P/E Ratio-5.33
EPS (TTM)$-0.21
ROE-1.27%
Fundamental Analysis

AI Price Forecasts

1 Week$1.03
1 Month$1.20
3 Months$1.65
1 Year Target$1.84

ALNFL.PA Stock Analysis & Investment Overview

Our comprehensive AI-powered analysis of NFL Biosciences SA (ALNFL.PA) provides investors with deep insights into the stock's performance, growth potential, and market positioning. With a Meyka AI Score of B, this stock demonstrates moderate investment characteristics based on our advanced machine learning models.

The current technical analysis reveals key indicators including an RSI of 48.06, suggesting the stock is in a neutral condition. Our forecasting models predict significant price movements, with a 12-month target of $1.84.

Key financial metrics showcase the company's fundamental strength, including a P/E ratio of -5.33 and a market capitalization of 14.2M. These metrics, combined with our AI analysis, provide a comprehensive view for both institutional and retail investors.

Technical Indicators

48.06RSI (14)
-0.03MACD
17.14ADX
Stats data is not available for ALNFL.PAStats details for ALNFL.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations data is not available for ALNFL.PAAnalyst Recommendations details for ALNFL.PA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Company Profile

NFL Biosciences SA, a biotechnology company, develops natural addiction withdrawal solutions for smokers. Its natural drug candidate in pipeline to cure tobacco addiction include NFL-101, a tobacco extract that is in Phase III clinical trial targeting smoking addiction; NFL-201, a cannabis and tobacco extract, which is in preclinical stage; and NFL-301, a botanical extract (traditional Chinese medicine) that is in preclinical stage. The company was incorporated in 2006 and is based in Castelnau-le-Lez, France.

CEO

Ignacio Faus

Employees

4

Headquarters

199 Rue Helene Boucher, Castelnau-le-Lez

Founded

2021

Frequently Asked Questions

;